PPA
VRDN icon

Parametric Portfolio Associates’s Viridian Therapeutics VRDN Stock Holding History

Parametric Portfolio Associates’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,292
Closed -$40K – 4001
2019
Q2 		$40K Sell
1,292
-62
-5% -$2.49K ﹤0.01% 3926
2019
Q1 		$57K Buy
1,354
+506
+60% +$22.9K ﹤0.01% 3877
2018
Q4 		$39K Buy
+848
New +$49K ﹤0.01% 3865

Other funds holding VRDN

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parametric Portfolio Associates's VRDN Position: Q3 2019 in Review

Parametric Portfolio Associates sold out of Viridian Therapeutics (VRDN) in Q3 2019, closing a stake of 1,292 shares — an estimated $40K sold.

Parametric Portfolio Associates first reported a position in VRDN in Q4 2018 and held it in 3 quarters. The position peaked at $57K in Q1 2019. 33 funds tracked by Wall St. Rank hold VRDN as of Q3 2019.

  • Parametric Portfolio Associates reported no remaining Viridian Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Parametric Portfolio Associates sold 1,292 Viridian Therapeutics shares in Q3 2019, an estimated $40K.
  • Parametric Portfolio Associates first reported a position in Viridian Therapeutics in Q4 2018 and held it in 3 quarters.
  • Parametric Portfolio Associates's Viridian Therapeutics position peaked at $57K in Q1 2019.
  • 33 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2019.

Based on Parametric Portfolio Associates's 13F filing for Q3 2019, filed 15 Nov 2019.